The TEL-AML1 fusion transcript, resulting from t(21;21) (p13;q22), is the most frequent molecular abnormality in precursor B acute lymphoblastic leukemia (ALL) cases. 1 The breakpoint region in the TEL gene is typically found in intron 5. Two breakpoints have been described within the AML1 gene. One in intron 1 resulting in the standard TEL-AML1 fusion transcript. The other breakpoint occurs in intron 2 and results in a variant fusion transcript, which is 39 nucleotides shorter and lacks exon 2 of the AML1 gene. In diagnostic RT-PCR tests, the majority of TEL-AML1-positive ALL blasts express the standard transcript. Some patients express the two transcripts, whereas only a minority express the variant (shorter) transcript. 2 We detected a novel TEL-AML1 fusion transcript by RT-PCR that resulted in a product longer than the standard transcript ( Figure 1a ). Sequence analysis revealed the in-frame insertion of 33 nucleotides between exon 5 of TEL and exon 2 of AML1 genes ( Figure 1b ). The 33 nucleotides are derived from BCL-G gene median form (Genbank accession AY040274.1) and correspond to exon 4 of the genomic sequence (NT_009714). BCL-G, also known as (BCL-2 like 14), is a proapoptotic member of the Bcl-2 family 3 and has been mapped to chromosomal band 12p13 in close proximity to TEL gene. 4 The leukemic blasts expressing the novel TEL-BCLG-AML1 transcript were isolated from a 6.5-year-old boy diagnosed with precursor B ALL. The patient underwent treatment according to a standard risk chemotherapy protocol for a duration of 2.5 years. At 2 years and 2 months after completion of chemotherapy, a late isolated bone marrow relapse developed. The leukemic blasts at the initial diagnosis of ALL and at the time of relapse harbored a t(12;21) and del(12)(p13) that was detectable by fluorescence in situ hybridization and expressed the same TEL-BCLG-AML1 fusion transcript (Figure 1) .
In our institutional experience of molecular testing in precursor B ALL (July 2000-February 2006), we detected TEL-AML1 fusion transcript by RT-PCR in 62 out of 222 cases (27.9%). Seven out of 62 cases showed only the variant transcript that lacks exon 2 of AML1 gene. The case presented here is the only case with a novel fusion gene involving a third gene and detected by the primers used in our test. 2 Typically, the presence of a TEL-AML1 fusion transcript is associated with a favourable prognosis and current treatment approaches for this group of patients aim at reductions of treatment intensity. To our knowledge this is the first description of a variant TEL-AML1 fusion gene involving a gene whose function is implicated in apoptosis. Although the biological significance of this event is currently unknown, our case highlights the rare occurrence of novel TEL-AML1 fusion transcripts. 
